lopinavir/ritonavir 133.33 + 33.3 mg capsules (Kaletra®) |
Abbott |
All African countries and the Least Developed Countries (LDCs) outside of Africa. |
Governments, NGOs, UN system organisations, and other national and international health institutions. |
US$ 500/year
(0.228/unit) |
|
FOB |
lopinavir/ritonavir oral solution 300 ml (Kaletra®) |
Abbott |
All African countries and the Least Developed Countries (LDCs) outside of Africa. |
Governments, NGOs, UN system organisations, and other national and international health institutions. |
US$ 41.67 per bottle |
|
FOB |
3TC + ZDV 300 mg + 150 mg tablets (Combivir®) |
GlaxoSmithKline |
LDCs plus sub-Saharan Africa.
All projects fully financed by the Global Fund to fight AIDS, TB and Malaria.
(For middle income developing countries public sector prices negotiated on a case-by-case basis bilaterally or through the AAI.)
|
Governments, aid organisations, charities, international, UN agencies, other not-for-profit organisations and international purchase funds such as the Global Fund to fight AIDS, TB & Malaria.
In sub-Saharan Africa, employers there who offer HIV/AIDS care and treatment directly to their staff through workplace clinics or similar arrangements are also eligible.
All organisations must supply the preferentially priced products on a not for profit basis.
|
US$ 329/year
(US$ 0.450/unit) |
Supply Agreement required.
(For NGOs requiring less than 10 patients packs per month, this requirement may be waived.)
|
CIP |
abacavir + 3TC + ZDV 300 + 150 + 300 mg tablets (Trizivir®) |
GlaxoSmithKline |
LDCs plus sub-Saharan Africa.
All projects fully financed by the Global Fund to fight AIDS, TB and Malaria.
(For middle income developing countries public sector prices negotiated on a case-by-case basis bilaterally or through the AAI.)
|
Governments, aid organisations, charities, international, UN agencies, other not-for- profit organisations and international purchase funds such as the Global Fund to fight AIDS, TB & Malaria.
In sub-Saharan Africa, employers there who offer HIV/AIDS care and treatment directly to their staff through workplace clinics or similar arrangements are also eligible.
All organisations must supply the preferentially priced products on a not for profit basis.
|
US$ 1241/year
(US$ 1.700/unit) |
Supply Agreement required. (For NGOs requiring less than 10 patients packs per month, this requirement may be waived.)
The manufacturer recommends that ‘prescribers must ensure that patients are fully informed regarding hypersensitivity reaction to abacavir. Patients developing signs or symptoms of hypersensitivity must contact their doctor immediately for advice.’
|
CIP |
Loading...
